Clinical Trial Update: Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of oral ENMD-2076 in ovarian, fallopian tube, and peritoneal cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• ENMD-2076 (ENMD-2076)

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Ovarian Cancer, Fallopian Cancer | Phase 2 | Status: COMPLETED